The purpose of this study is to understand the role of a dietary oil to alter chronic disease risk factors in women who are at risk for heart disease and/or diabetes. The investigator's previous study showed that safflower oil reduced trunk fat mass in women with diabetes. The investigators believe safflower oil can also attenuate criteria of metabolic syndrome through reduction in trunk fat mass.
The long-term goal is to develop effective and novel dietary and lifestyle strategies to reduce the progression of metabolic syndrome to chronic diseases such as coronary heart disease. The rationale for conducting this research study is that there are few effective strategies that target changes in body composition and metabolism as a means to attenuate metabolic syndrome. The investigators plan to test the central hypothesis and accomplish the overall objective of this research by pursuing the following three specific aims. Specific Aim 1: Quantify the extent that linoleic acid reduces trunk adipose mass in women with metabolic syndrome. Specific Aim 2: Measure changes in visceral adipose tissue Specific Aim 3: Determine the time-dependent effect of linoleic acid to increase adiponectin levels.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
18
2 tsp per day (\~10g of oil)
The Ohio State University Exercise Physiology Lab
Columbus, Ohio, United States
Changes in trunk adipose mass
Time frame: Baseline and Week 16 (end of the study)
Changes in Alpha and Gamma Tocopherol Levels
Time frame: Baseline through Week 16 (end of the study)
Changes in mood
Mood questionnaires will be completed at each study visit
Time frame: Baseline through Week 16 (end of the study)
Changes in Lipid Profile
Time frame: Baseline through Week 16 (end of the Study)
Oil Supplementation Compliance
Plasma and red blood cell fatty acid composition will be analyzed. Returned oil containers will be weighed to estimate oil consumption.
Time frame: Baseline through Week 16 (end of the study)
Changes in glycemic control
Serum glucose and insulin levels will be analyzed
Time frame: Baseline through Week 16 (end of the study)
Changes in lean mass
Time frame: Baseline and Week 16 (end of the study)
Changes in visceral adipose tissue
Time frame: Baseline and Week 16 (end of study)
Changes in adipocytokine levels
Adiponectin, leptin, and IL-6 will be analyzed
Time frame: Baseline through Week 16 (end of the study)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.